Buy



# **HCL Technologies**

# Estimate change TP change Rating change

Bloomberg	HCLT IN
Equity Shares (m)	2714
M.Cap.(INRb)/(USDb)	5036.3 / 59.9
52-Week Range (INR)	1866 / 1212
1, 6, 12 Rel. Per (%)	3/10/21
12M Avg Val (INR M)	4807

### Financials & Valuations (INR b)

rions (mar	וטו	
FY25E	FY26E	FY27E
1,173	1,291	1,419
18.2	18.9	18.9
174	196	218
63.7	71.9	80.3
10.1	12.9	11.6
247	245	241
25.6	29.3	33.1
22.7	26.3	29.3
90.0	90.0	90.0
		_
29.3	25.9	23.2
7.5	7.6	7.7
19.6	17.2	15.6
3.1	3.5	3.9
	FY25E 1,173 18.2 174 63.7 10.1 247 25.6 22.7 90.0 29.3 7.5 19.6	1,173 1,291 18.2 18.9 174 196 63.7 71.9 10.1 12.9 247 245  25.6 29.3 22.7 26.3 90.0 90.0  29.3 25.9 7.5 7.6 19.6 17.2

### Shareholding pattern (%)

As On	Jun-24	Mar-24	Jun-23
Promoter	60.8	60.8	60.8
DII	15.8	15.0	15.4
FII	18.7	19.9	19.2
Others	4.7	4.3	4.6

FII Includes depository receipts

### Leading the bounce-back

CMP: INR1,865

### Broad-based growth and outlook reinforce HCLT as our top pick

HCL Technologies (HCLT) reported a muscular 2QFY25, with revenue of USD3.4b, up 1.6% QoQ (~2.5% organic) and 6.2% YoY in constant currency (CC), above our estimate of flat revenue growth. EBIT margins came in at 18.6%, beating our estimate of 17.4%. New deal TCV stood at USD 2.2b (up 13% QoQ) in 2QFY25. For FY25, HCLT revised the lower end of its growth guidance to 3.5%-5% YoY in CC from 3%-5% earlier. For 1HFY25, revenue/EBIT/PAT grew 7.5%/8.1%/15.3% compared to 1HFY24.

TP: INR2,300 (+23%)

- Our view: Growth was broad-based, supported by robust deal wins, underscoring our thesis that the tide around client behavior is turning. The CQGR ask rate for 2HFY25 to achieve the top end of the guidance is now fairly benign at 0-2% cc; we believe a difficult geopolitical backdrop, coupled with client-specific troubles in automotive ER&D, could be informing some of this caution. As highlighted in our Sept'24 thematic report (<u>Technology: Bounce-back! Charting the path to revival for IT services</u>), we anticipate key sectors such as healthcare, manufacturing, and BFSI to drive growth recovery. Additionally, within service lines, we expect data engineering and ERP modernization (especially SAP S4HANA) to lead the way; areas where HCL has a strong advantage over peers.
- **Guidance:** HCLT revised the lower end of its guidance; it now expects overall revenues and services revenues to grow by 3.5%-5% in constant currency terms (3-5% earlier). It kept the EBIT margin guidance unchanged at 18-19%.
- Margins: Better-than-expected growth in its high-margin product business and a recovery in its ER&D business lifted margins to 18.6% in 2Q. We expect 2H to witness some headwinds, such as furloughs and wage hikes; however, a seasonally strong quarter for the product business (3Q) and a more measured wage hike cycle should keep EBIT margins comfortably within the guided range.
- HCLT tops our Impact Framework for large-caps: HCLT remains our top pick among large-cap IT companies, based on our IMPACT framework. We see HCLT is best positioned to play the short-term slow, medium-term fast GenAI revolution. HCLT's capabilities are comparable to the best in the industry, especially when it comes to new-age projects.
- Valuations and changes in estimates: We expect HCLT to deliver 18.2% EBIT margin in FY25. This should recover to 18.9% in FY26 as growth improves. We expect HCLT to deliver a CAGR of 8.4%/11.5% in USD revenue/INR PAT over FY25-27E. We raise our EPS estimates by 2.4%/2.7%/3.4% for FY25/FY26/FY27 as we factor in the 2Q performance and a recovery in discretionary spending in 2HFY25/FY26E. Reiterate BUY with a TP of INR2,300 (based on 30x Sep'26E EPS).

Abhishek Pathak - Research analyst (Abhishek.Pathak@MotilalOswal.com)

### Beat on revenue growth and margins

- Revenue grew 1.6% QoQ in CC vs. our estimate of flat revenue growth. New deal TCV stood at USD2.2b (up 13.2% QoQ, down 44.1% YoY) in 2QFY25.
- IT business/ER&D business/P&P grew by 1.8%/1.1%/1.4% QoQ CC.
- EBIT margin was 18.6% vs. our estimate of 17.4%.
- For FY25, revenue growth guidance was upgraded to 3.5-5% YoY in CC (similar for Services) from 3%-5% earlier. EBIT margin guidance was maintained at 18.0-19.0% in FY25.
- PAT inched down 0.5% to INR42b (up 10.5% YoY) vs. our est. of INR39b.
- LTM attrition was up 10bp QoQ to 12.9%. Net employee headcount declined 0.4% QoQ in 2QFY25. HCLT added 2,932 freshers in this quarter.
- LTM FCF to Net Income stood at 119%.
- The management declared a dividend of INR12/share.

### Key highlights from the management commentary

- 2Q growth was broad-based across segments, barring the financial services vertical, which was impacted by the State Street divestment.
- Incremental demand improved in 2Q across multiple verticals. Growth was driven by the ramp-up of deals signed in the last few quarters, as well as data and SAP application modernization program.
- Two key factors driving 2Q growth: (1) ramp-up of deals signed in the last 2-3 quarters, and (2) increased demand for data/SAP and the initial ramp-up of large application modernization opportunities.
- Furloughs in 3Q are expected to be similar to last year.
- **Financial Services**: Revenue declined 4.5% YoY in CC, primarily due to the USD30m impact of the State Street divestment. BFSI is looking better from the discretionary spending perspective.
- Manufacturing: There is pressure on the automotive business in Europe, with a couple of large clients undergoing cost reductions.
- **Guidance:** The lower end of revenue growth guidance was increased; 2% growth is needed in 3Q/4QFY25 to achieve the upper end guidance of 5%. This growth assumes similar furloughs and the execution of deals signed in recent quarters. EBIT margin guidance was maintained at 18-19%.

### Valuation and view

We believe HCLT is best positioned to play the short-term slow, medium-term fast GenAI revolution. Its investments in next-gen platforms also position it well for a recovery in client spends. We value HCLT at 30x Sep'26E EPS. Reiterate BUY with a TP of INR2,300 (implying 23% upside potential). HCLT remains our top pick among large-cap IT companies.

Quarterly performand	ce											(INR b)
Y/E March		FY2	4			FY2	5E		FY24	FY25E	Est.	Var.
	1Q	2Q	<b>3Q</b>	4Q	1Q	<b>2Q</b>	3QE	4QE			2QFY25	(%/bp)
Revenue (USD m)	3,200	3,225	3,415	3,430	3,364	3,445	3,577	3,608	13,270	13,994	3,379	1.9
QoQ (%)	-1.1	0.8	5.9	0.4	-1.9	2.4	3.8	0.9	5.4	5.5	0.5	196bp
Revenue (INR b)	263	267	284	285	281	289	300	303	1,099	1,173	283	1.9
YoY (%)	12.1	8.0	6.5	7.1	6.7	8.2	5.6	6.4	8.3	6.7	6.2	205bp
GPM (%)	35.6	36.2	36.7	35.0	34.5	34.9	34.0	35.5	35.9	34.7	35.0	-10bp
SGA (%)	13.6	12.4	11.5	12.0	12.4	11.5	11.0	11.5	12.4	11.6	12.5	-104bp
EBITDA	55	59	67	61	58	64	65	68	242	255	59	7.4
EBITDA margin (%)	20.8	22.3	23.5	21.4	20.7	22.1	21.6	22.6	22.0	21.8	21.0	113bp
EBIT	45	49	56	50	48	54	54	58	200	213	49	8.7
EBIT margin (%)	17.0	18.5	19.7	17.6	17.1	18.6	18.0	19.0	18.2	18.2	17.4	116bp
Other income	2	2	3	3	9	3	4	4	9	20	3	-4.3
ETR (%)	24.8	25.3	25.9	24.2	25.4	25.5	25.5	25.5	25.1	25.5	26.0	-50bp
Adjusted PAT	35	38	44	40	43	42	43	46	157	174	39	8.6
QoQ (%)	-11.2	8.4	13.5	-8.4	6.8	-0.5	1.5	6.2			-8.4	787bp
YoY (%)	7.6	9.8	6.2	0.1	20.5	10.5	-1.2	14.5	5.7	10.5	1.8	875bp
EPS	13.0	14.1	16.0	14.7	15.7	15.6	15.8	16.8	57.9	63.7	14.2	10.3

Y/E March		FY2	24		FY25E			
	1Q	2Q	3Q	4Q	1Q	2Q		
Revenue (QoQ CC %)	-1.3	1.0	6.0	0.3	-1.6	1.6		
Costs (% of revenue)								
COGS	64.4	63.8	63.3	65.0	65.5	65.1	64.1	
SGA	13.6	12.4	11.5	12.0	12.4	11.5	12.4	
Margins								
Gross Margin	35.6	36.2	36.7	35.0	34.5	34.9	35.9	
EBIT Margin	17.0	18.5	19.7	17.6	17.1	18.6	18.2	
Net Margin	13.4	14.4	15.3	14.0	15.2	14.7	14.3	
Operating metrics								
Headcount (k)	223	221	225	227	219	219	227	
Attrition (%)	16.3	14.2	12.8	12.4	12.8	12.9	12.4	
Key Verticals (YoY CC %)								
BFSI	14.4	12.5	12.9	12.1	-1.3	-4.5	12.1	
Manufacturing	16.5	3.3	5.8	9.8	3.5	7.1	9.8	
Key Geographies (YoY CC %)								
North America	7.3	3.9	6.7	6.8	8.0	7.5	6.8	
Europe	10.5	3.9	1.7	5.5	3.0	4.2	5.5	

Exhibit 1: QoQ growth trend in HCL Software





Exhibit 2: QoQ growth trend in HCL Services



Source: MOFSL, Company Source: MOFSL, Company

Exhibit 3: HCLT and LTIM lead in the IMPACT ranking among Tier-1 companies

IMPACT framework- large caps	Industry exposure (5- best)	Margin expansion (5- best)	Partnerships (5- best)	Automation threat (5: minimum)	Client strategies (5-best)	NextGen readiness (5-best)	Total Score
HCL	••••	•••	••••	••••		•••	24
LTIM	••••	•	••••	••••	000	••••	24
Infosys	•••	•••	••••	•••	•••	••••	22
TCS	•••	•••	••••	•••	•••	••••	22
Wipro	•••	•••	••••	•••	•••	•••	20
TechM	•	•••	••••	•••	•••	•••	18

Source: MOFSL

Exhibit 4: PSYS leads in the IMPACT ranking among Tier-2 companies

IMPACT framework- mid tier	Industry exposure (5- best)	Margin expansion (5- best)	Partnerships (5- best)	Automation threat (5: minimum)	Client strategies (5-best)	NextGen readiness (5-best)	Total Score
Persistent	••••		••••	••••	••••	••••	28
Coforge	••••	•••	••••	•••	••••	•••	24
Zensar	•••	•••	•••	••••	••••	•••	22
LTTS	•••	•••	•••	••••	••••	•••	22
Mphasis	•••	•••	••••	•••	•••	•••	20
Cyient	•••	•••	•	••••	••••	•••	20

Source: MOFSL



### Key highlights from the management commentary Demand and industry outlook

- 2Q growth was broad-based across segments, barring the financial services vertical, which was impacted by the State Street divestment.
- Incremental demand improved in 2QFY25 across multiple verticals. Growth was driven by the ramp-up of deals signed in the last few quarters, as well as data and SAP application modernization program.
- Two key factors driving 2Q growth: (1) ramp-up of deals signed in the last 2-3 quarters, and (2) increased demand for data/SAP and the initial ramp-up of large application modernization opportunities.
- The pipeline continues to grow, with S4HANA migration driving demand for SAP. Total TCV was USD2.2b, with a total of 20 deals signed: 8 in the software business and 12 in the services business (IT and ER&D).
- The pipeline for ER&D continues to expand. Further, the management expects good bookings for the rest of the year.
- The pipeline shows significant opportunities in SAP (due to S/4HANA) as well as in data and AI; the total overall pipeline is near an all-time high.
- For FY25, the lower end of revenue growth guidance was upgraded to 3.5%-5% YoY in CC (similar for Services), compared to the previous range of 3%-5%.
- 2% growth is needed in 3Q and 4Q to achieve the upper-end guidance of 5%. This growth assumes similar furloughs and the execution of deals signed in recent quarters.
- EBIT margin guidance remains at 18.0%-19.0% for FY25.
- In the Financials vertical, revenue declined 4.5% YoY CC, primarily due to the USD30m impact of the State Street divestment. Growth was strong across all markets (Americas, Europe) and segments (insurance, fintech). BFSI is looking better from the discretionary spending perspective.
- In Manufacturing, there is pressure on the automotive business in Europe, with a couple of large clients undergoing cost reductions. The ramp-up of the SAP business in manufacturing is offsetting some of the impacts from aerospace clients.
- In ER&D, the automotive sector is facing pressure in Europe and is expected to experience more pressure in 3Q.
- There is good traction in: (1) the AI Force platform (25 clients so far, with a target of 50), (2) HCLT Tech AI Foundry (helping with data-led modernization), and (3) continued experience in AI labs.
- Recent GenAI-based acquisitions in Europe are noteworthy. Zeenea, based out of Paris, will help HCL Software grow in the areas of GenAI and data modernization.
- There have been significant achievements in GenAl, with Al Force gaining widespread adoption.
- Growth drivers for HCLSoftware include: (1) customer renewals, (2) sharper product growth in platforms, data, and AI, (3) significant focus on emerging markets like the Middle East, India, and South Asia, and (4) a 360-degree ecosystem.
- A 23-25% margin range is considered comfortable for P&P. HCLT Software's annual recurring revenue (ARR) stood at USD1.05b. Robustness in the portfolio

- is coming from innovation and product features—HCL Unica, integrated with customer data platforms, is leading to renewals and increased fees.
- In the medium term, HCLT expects mid-single-digit growth in P&P business, which will improve margins.

### Margin performance

- EBIT margin stood at 18.6%. FCF conversion on an LTM basis was 119%.
- In 3Q, there will be a 65-80bp impact from wage hikes and the remaining 50-60bp impact in 4Q.
- EBIT margin declined by 50bp QoQ to 17.1% in 1QFY25.
- Margin walk: The margin improvement of 149bp QoQ in 2Q included 54bp from software (driven by operational leverage), 110bp from services due to operational efficiency and reduced marketing spending, and 22bp from favorable exchange movements.
- Net profit was marginally down due to one-offs, including exchange gains in the last quarter related to the State Street divestment.
- 3Q is expected to be the strongest quarter for the software business due to seasonality. The management maintained its FY25 margin guidance at 18-19%.

### Other highlights

- Wage has increased as the workforce shifts to a more specialized skill set.
- The total employee count was 218,621. LTM attrition was 12.9%, up 10bp QoQ but down 14.2% YoY.
- There has been a drop in headcount due to efficiency levers and increased demand for specialized skills.
- Wage hikes will be similar to last year, effective from Oct'24, with a higher proportion of lateral hiring. The average hike is 7%, while top performers (top executives) can expect wage increases in the range of 12-15%.
- Cash generation increased due to improved DSO days.
- HCLT declared a dividend of INR12 per share.

Exhibit 5: Americas and Europe regions performed well in 1QFY25

Geographies (YoY CC Growth, %)	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25
Americas	10.7	15.0	13.0	17.5	18.2	12.3	10.0	7.3	3.9	6.7	6.8	8.0	7.5
Europe	9.0	12.0	13.6	22.5	21.8	23.3	14.6	10.5	3.9	1.7	5.5	3.0	4.2
ROW	14.9	25.8	15.0	18.2	13.7	11.6	1.4	-6.0	-3.6	-7.5	-7.1	-3.6	-2.6


Source: Company, MOFSL

Exhibit 6: The growth was dragged down by Telecom and Technology in 1QFY24

Verticals (YoY CC Growth, %)	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25
Financial Services	6.3	13.5	10.2	16.4	15.4	8.8	9.6	14.4	12.5	12.9	12.1	-1.3	-4.5
Manufacturing	11.9	12.2	16.6	19.1	21.8	21.2	11.8	16.5	3.3	5.8	9.8	3.5	7.1
Technology & Services	10.8	18.1	14.3	34.2	26.6	19.3	17.9	-7.0	-9.5	-9.2	-8.6	2.7	5.6
Retail & CPG	3.6	11.5	6.0	5.8	11.9	-3.8	11.8	3.2	8.1	11.7	8.2	9.7	6.2
Telecommunications, Media, Publishing & Entertainment	13.4	12.4	20.2	29.2	27.1	27.9	8.9	-11.7	-10.4	8.3	6.5	69.2	61.2
Lifesciences & Healthcare	20.1	21.3	18.5	15.7	14.4	19.5	1.6	13.4	9.8	0.5	5.4	-4.1	-2.8
Public Services#	8.8	14.8	7.8	15.2	17.6	16.7	7.6	6.8	1.7	-0.6	0.1	-3.7	-2.0

Source: Company, MOFSL

Exhibit 7: IT Services witnessed YoY growth of 6.8 % in USD terms in 2QFY25



Source: Company, MOFSL

### Valuation and view

We believe HCLT is best positioned to play the short-term slow, medium-term fast GenAl revolution. Its investments in next-gen platforms also position it well for a recovery in client spends. We value HCLT at 30x Sep'26E EPS. Reiterate BUY with a TP of INR2,300 (implying 23% upside potential). HCLT remains our top pick among large-cap IT companies.


**Exhibit 8: Revised estimates** 

		Revised			Earlier		Change			
	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	
USD:INR	83.7	84.0	84.0	83.6	83.6	83.6	0.1%	0.5%	0.5%	
Revenue (USD m)	13,994	15,364	16,892	13,916	15,282	16,754	0.6%	0.5%	0.8%	
Growth (%)	5.5	9.8	9.9	4.9	9.8	9.6	60bps	0bps	30bps	
EBIT margin (%)	18.2	18.9	18.9	18.2	18.9	18.9	0bps	0bps	0bps	
PAT (INR b)	174	196	218	171	193	214	1.3%	1.5%	1.8%	
EPS	63.7	71.9	80.3	62.2	70.0	77.6	2.4%	2.7%	3.4%	

Source: MOFSL


### **Story in charts**

Exhibit 9: TCV (new deal wins) at USD2,218m, up by 13% QoQ; book-to-bill at 0.6x




Source: Company, MOFSL

Exhibit 10: Margin jumps due strong performance by services in 2QFY25




Source: Company, MOFSL

Exhibit 11: HCLT continues to report industry-leading growth



\*Infosys yet to report


Exhibit 12: HCLT's FCF conversion is at par with peers\*



\*Infosys yet to report

Source: Company, MOFSL

Exhibit 13: HCLT now has reached valuation parity with INFO



Source: Bloomberg, MOFSL

## **Operating metrics**

**Exhibit 14: Operating metrics** 

	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25
Service-wise (%)									
IT and Business Services	73.6	71.7	73.8	74.7	74.6	71.7	74.4	74.5	74.6
Engineering and R&D Services	17.0	16.6	16.1	15.4	16.0	16.4	16.1	15.9	15.8
Products and Platform	9.4	11.7	10.1	9.9	9.4	11.9	9.5	9.6	9.9
Vertical-wise (Services) (%)									
BFSI	20.6	19.9	21.2	22.6	22.6	21.7	21.6	21.0	20.5
Manufacturing	18.3	18.3	19.0	19.0	19.0	20.1	20.4	19.0	19.0
Technology and Services	15.4	15.4	14.4	14.4	14.4	12.8	12.3	14.4	14.4
Retail and CPG	9.2	8.9	9.0	9.1	9.6	9.6	9.1	9.4	9.6
Telecom MP&E	9.2	9.4	8.8	7.6	8.0	9.7	11.5	12.2	12.1
Life Sciences	16.5	17.1	17.5	17.5	17.5	16.4	16.3	15.9	16.0
Public Services	10.2	10.2	10.2	10.0	9.9	9.7	8.8	9.1	9.2
Geography-wise (Services) (%)									
US	64.8	63.5	63.8	64.5	64.5	64.5	65.2	66.0	65.1
Europe	27.5	29.1	28.9	28.7	28.5	29.0	28.9	27.9	28.4
RoW	7.7	7.4	7.3	6.8	7.0	6.4	5.9	6.1	6.5
Client-wise (%)									
Top five clients	10.7	10.3	10.1	9.8	9.8	9.8	10.4	11.4	12.1
Top 10 clients	18.8	18.2	17.7	17.2	17.2	17.7	18.8	19.6	20.1
Top 20 clients	28.6	28.2	27.8	27.2	27.3	28.0	29.0	30.1	30.8

Source: Company, MOFSL:

### **Financials and valuations**

Income Statement								(INR b)
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27I
Sales	707	754	857	1,015	1,099	1,173	1,291	1,419
Change (%)	17.0	6.7	13.6	18.5	8.3	6.7	10.0	9.9
Cost of Goods Sold	453	467	546	662	721	782	842	928
Gross Profit	254	287	311	353	378	391	448	491
Selling & Admin Exp.	87	93	109	127	136	136	158	172
EBITDA	167	193	202	226	242	255	290	319
% of Net Sales	23.6	25.6	23.6	22.3	22.0	21.8	22.5	22.5
Depreciation	28	40	40	41	42	42	46	51
EBIT	139	153	162	185	200	213	244	268
% of Net Sales	19.6	20.4	18.9	18.2	18.2	18.2	18.9	18.9
Other Income	2	7	8	10	9	20	19	25
РВТ	140	160	170	195	210	233	263	292
Тах	29	41	34	46	53	59	67	75
Rate (%)	20.9	25.4	20.3	23.8	25.1	25.5	25.5	25.5
EO Item (net)	0	0	0	0	0	0	0	C
Minority interest	0	1	0	0	0	0	0	C
Adjusted PAT	111	119	135	148	157	174	196	218
Change (%)	9.3	7.4	13.7	9.9	5.7	10.5	12.9	11.2
Balance Sheet								(INR b)
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Reserves	517	615	620	654	683	674	664	653
Net Worth	517	615	620	654	683	674	664	653
Loans	51	39	39	21	22	22	22	22
Other liabilities	55	55	43	45	66	68	72	76
Capital Employed	623	709	703	720	771	763	758	751
Gross Block	511	546	560	596	643	672	698	726
Less : Depreciation	128	168	208	249	291	333	379	431
Net Block	383	378	352	347	352	339	319	296
0.1	CF	<u></u>			F2	F2	F2	- ·

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Reserves	517	615	620	654	683	674	664	653
Net Worth	517	615	620	654	683	674	664	653
Loans	51	39	39	21	22	22	22	22
Other liabilities	55	55	43	45	66	68	72	76
Capital Employed	623	709	703	720	771	763	758	751
Gross Block	511	546	560	596	643	672	698	726
Less: Depreciation	128	168	208	249	291	333	379	431
Net Block	383	378	352	347	352	339	319	296
Other assets	65	69	57	51	52	52	53	54
Investments	105	140	85	112	178	178	178	178
Curr. Assets	<b>27</b> 9	291	397	425	416	437	475	516
Debtors	178	175	207	255	255	270	295	321
Cash & Bank Balance	38	65	105	91	95	96	103	110
Other Current Assets	64	50	85	80	66	71	78	85
Current Liab. & Prov	209	168	188	214	227	242	267	293
Net Current Assets	70	123	209	211	189	194	208	223
Application of Funds	623	709	703	720	771	763	758	751

### **Financials and valuations**

Ratios								
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Diluted (INR)								
EPS	40.7	43.8	49.8	54.8	57.9	63.7	71.9	80.3
Cash EPS	51.2	58.5	64.6	70.1	73.3	79.1	89.0	99.1
Book Value	190.4	226.7	228.6	241.6	252.1	247.5	245.0	240.8
DPS	8.0	26.0	44.0	48.0	48.0	57.4	64.7	72.2
Payout (%)	19.6	59.4	88.3	87.6	82.9	90.0	90.0	90.0
Valuation (x)								
P/E	45.8	42.6	37.4	34.0	32.2	29.3	25.9	23.2
Cash P/E	36.4	31.9	28.9	26.6	25.5	23.6	21.0	18.8
EV/EBITDA	30.4	26.0	24.7	22.0	20.6	19.6	17.2	15.6
EV/Sales	7.2	6.7	5.8	4.9	4.5	4.3	3.9	3.5
Price/Book Value	9.8	8.2	8.2	7.7	7.4	7.5	7.6	7.7
Dividend Yield (%)	0.4	1.4	2.4	2.6	2.6	3.1	3.5	3.9
Profitability Ratios (%)								
RoE	23.6	21.0	21.9	23.3	23.5	25.6	29.3	33.1
RoCE	21.3	18.7	19.6	21.1	21.7	22.7	26.3	29.3
<b>Turnover Ratios</b>								
Debtors (Days)	92	85	88	92	85	84	83	83
Asset Turnover (x)	1.8	2.0	2.4	2.9	3.1	3.5	4.1	4.8
Cash Flow Statement								(INR b)
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
CF from Operations	149	166	174	193	201	215	242	269
Chg. in Working Capital	-16	30	-5	-13	23	-2	-4	-4
Net Operating CF	134	196	169	180	224	213	238	264
Net Purchase of FA	-18	-18	-16	-14	-10	-29	-26	-28
Net Purchase of Invest.	-105	-40	30	-25	-57	0	0	0
Net Cash from Inv.	-124	-57	15	-39	-67	-29	-26	-28
Issue of shares/other adj.	0	0	0	0	0	0	0	0
Proceeds from LTB/STB	-15	-79	-31	-29	-14	0	0	0
Dividend Payments	-16	-33	-114	-130	-141	-183	-205	-229
Net CF from Finan.	-32	-112	-145	-159	-154	-183	-205	-229
Free Cash Flow	115	179	153	166	214	184	212	236
Net Cash Flow	-22	27	39	-18	3	1	7	7
Forex difference	0	1	1	4	1	0	0	0
Opening Cash Balance	60	38	66	106	91	95	97	103
Closing Cash Balance	38	66	106	91	95	97	103	110

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

### NOTES

Explanation of Investment Rating					
Investment Rating	Expected return (over 12-month)				
BUY	>=15%				
SELL	< - 10%				
NEUTRAL	> - 10 % to 15%				
UNDER REVIEW	Rating may undergo a change				
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation				

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at http://online

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

MOFSL, it's associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

In the past 12 months, MOFSL or any of its associates may have:

- received any compensation/other benefits from the subject company of this report
- b)
- managed or co-managed public offering of securities from subject company of this research report, received compensation for investment banking or merchant banking or brokerage services from subject company of this research report, c)
- received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report. d)
- MOFSL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.

(b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures. To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

### **Analyst Certification**

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement	HCL Technologies
Analyst ownership of the stock	No

A graph of daily closing prices of securities is available at <a href="www.nseindia.com">www.nseindia.com</a>, <a href="www.nseindia.com</a>, <a href="www.nseindia.com">www.nseindia.com</a>, <a href="www.nseindia.com">www.nseindia.co Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motifal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motifal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and

13 15 October 2024

services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motifal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act of Singapore .Accordingly, if a Singapore person is not, or ceases to be, such an investor, they must immediately discontinue any use of this Report and inform MOCMSPL.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No::022-40548085.

### Grievance Redressal Cell

Chovando Floarocca Con.						
Contact Person	Contact No.	Email ID				
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com				
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com				
Mr. Ajay Menon	022 40548083	am@motilaloswal.com				

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.